Scientific Advisors
Gary Borisy, Ph.D.Director and Chief Executive Officer, Dr. Borisy is Director and Chief Executive officer of The Marine Biological Laboratory (MBL), an international center for research, education and training in biology, biomedicine and ecology based in Woods Hole, MA. Prior to the MBL, Dr. Borisy was the Leslie B. Arey Professor of Cell and Molecular Biology at Northwestern University Medical School and a past president of the American Society of Cell Biology. An internationally recognized cell biologist, Dr. Borisy is known for his work on understanding the structure and functioning of living cells and for his important discovery of the protein tubulin. Dr. Borisy was the Chairman of the Laboratory of Molecular Biology at the University of Wisconsin, where he remains a professor emeritus. He has authored 200 peer reviewed scientific publications and has served as an advisor on numerous committees. Dr. Borisy received his B.S. in biochemistry and his Ph.D. in biophysics from the University of Chicago. Back to Top Michael A. Foley, Ph.D.Director, Chemical Biology Platform and Dr. Foley is currently Director of the Chemical Biology Platform and Director of Medicinal Chemistry at the Broad Institute, a research collaboration of MIT, Harvard and its affiliated hospitals and the Whitehead Institute. Dr. Foley is one of the scientific founders of CombinatoRx and a leading expert in solid-phase synthesis of stereochemically complex small molecules and medicinal chemistry. Dr. Foley was previously Vice President of Chemical Technologies at Infinity Pharmaceuticals. Dr. Foley was a fellow at the Harvard Institute of Chemistry and Cell Biology (ICCB), a joint academic institute between Harvard Medical School and the Graduate School of Arts and Sciences. Dr. Foley served as the Head of Chemical Technology for the ICCB. Prior to his academic faculty appointment, Dr. Foley worked in the pharmaceutical industry for more than 10 years, building up his base of expertise in medicinal chemistry at Bristol-Myers Squibb and Glaxo Wellcome. Dr. Foley earned his Ph.D. in chemistry at Harvard University in the laboratories of Dr. Stuart Schreiber, researching the interface of chemistry and biology. Back to Top Todd Golub, M.D.Director, Cancer Program, Broad Institute and Dr. Golub is currently Director of the Cancer Program of the Broad Institute, the Charles A. Dana Investigator at the Dana-Farber Cancer Institute, Associate Professor of Pediatrics at Harvard Medical School, and Investigator at the Howard Hughes Medical Institute. Dr. Golub received his medical degree from the University of Chicago, followed by clinical training in oncology at Harvard. He has served on numerous committees, including the pharmacy and therapeutics committee of the Dana-Farber Cancer Institute, has co-chaired National Cancer Institute progress review groups, and serves on multiple editorial and advisory boards. Dr. Golub is the recipient of numerous awards, including The Daland Prize of the American Philosophical Society, Discover Magazine Inventor of the Year (Health Category), and the American Association for Cancer Research's Award for Outstanding Achievement in Cancer Research. In addition to CombinatoRx, Dr. Golub serves as an advisor to several innovative biotechnology companies including Ardais Corporation and Infinity Pharmaceuticals, Inc. Back to Top Curtis T. Keith, Ph.D.Chief Scientific Officer Dr. Keith, co-founder of CombinatoRx, is Chief Scientific Officer for Harvard University's Office of Technology Development Accelerator Fund. Prior to joining Harvard, Dr. Keith served as a member of the CombinatoRx management team from 2000-2008, most recently as Senior Vice President of Research. Dr. Keith completed his Ph.D. in chemistry and chemical biology at Harvard University. Dr. Keith also holds a B.Sc. in biochemistry from McGill University. Back to Top Brent R. Stockwell, Ph.D.Assistant Professor, Department of Biological Sciences and Department of Chemistry, Dr. Stockwell is one of the scientific co-founders of CombinatoRx. Dr. Stockwell's research at Columbia involves application of chemical genetics to the study of orphan genetic diseases, including sarcomas, spinal muscular atrophy and Huntington's disease. Prior to joining the faculty of Columbia University, he was a fellow at the Whitehead Institute for Biomedical Research, where he developed new tools for chemical genetics and identified novel compounds with relevance to cancer and neurodegeneration. Dr. Stockwell studied organic chemistry and molecular biology during his graduate training under Stuart L. Schreiber in the Department of Chemistry and Chemical Biology at Harvard University. While at Harvard, he was awarded National Science Foundation and Howard Hughes Medical Institute Pre-doctoral Fellowships, and a number of teaching awards. Dr. Stockwell received his A.B. degree from Cornell University, graduating Summa cum Laude with membership in Phi Beta Kappa and a dual major in chemistry and economics. In 2002, he was awarded a Career Award at the Scientific Interface from the Burroughs Wellcome Fund for his interdisciplinary research. Back to Top |
|
 |
